AstraZeneca Keeps R&D Focus, Spins Out Phase II Neuromyelitis Optica MAb Into New Biotech

 
• By John Davis

Six early-stage biologics with potential to treat inflammation and auto-immunity disorders have been spun out of AstraZeneca's biologics arm, MedImmune, into a stand-alone Chinese investor-backed company, Viela Bio, underlining the commitment of the big pharma to its three areas of therapeutic focus.

Vortex
Spinning off non-core assets has been a feature of AstraZeneca's business development • Source: Shutterstock

More from Immunological

More from Therapy Areas